Amit Chunilal Nathwani
Oprichter bij Freeline Therapeutics Ltd.
Actieve functies van Amit Chunilal Nathwani
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Directeur/Bestuurslid | 01-01-2015 | - |
Hoofd Techniek/Wetenschap/O&O | 01-01-2015 | - | |
Oprichter | 01-01-2015 | - | |
University College London | Corporate Officer/Principal | 01-11-2011 | - |
Royal Free Hospital Medical School | Corporate Officer/Principal | 01-11-2012 | - |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Directeur/Bestuurslid | - | - |
Algemeen Directeur | - | - | |
Oprichter | 01-01-2019 | - |
Loopbaan van Amit Chunilal Nathwani
Eerdere bekende functies van Amit Chunilal Nathwani
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
FREELINE THERAPEUTICS HOLDINGS PLC | Directeur/Bestuurslid | 26-06-2020 | 04-04-2023 |
Hoofd Techniek/Wetenschap/O&O | 20-08-2021 | 01-03-2022 | |
Oprichter | 01-01-2015 | 04-04-2023 | |
Independent Dir/Board Member | 03-04-2020 | 04-04-2023 |
Opleiding van Amit Chunilal Nathwani
University of Aberdeen | Undergraduate Degree |
The Open University | Doctorate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 8 |
Operationeel
Director/Board Member | 3 |
Founder | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Sectoraal
Consumer Services | 5 |
Health Technology | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |